

From: Alicea, Candido
Sent: Monday, August 20, 2018 3:15 PM
To: 'joan.robertson@grifols.com'
Cc: Riggins, Patrick
Subject: BLA 125683/0 PNR Request

Dear Joan,

This email is to follow-up on a voice message I just left in your in-box. I am contacting you today to inform you that the Proprietary Name Review reviewer has found that your proposed primary PNR submitted (b) (4) will not be approvable. The reviewer has recommended that you submit a request to have the alternate name proposal (b) (4) reviewed, as this one seems to be acceptable. Please send your request as soon as possible, and acknowledge receipt of this email.

Best regards,

Candido

Cándido Alicea Ph.D.
CDR, USPHS
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8310
Fax: 301-595-1303
candido.alicea@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."